A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma Journal Article
| Authors: | Kelly, C. M.; Qin, L. X.; Whiting, K. A.; Richards, A. L.; Avutu, V.; Chan, J. E.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Nacev, B. A.; Rosenbaum, E.; Adamson, T.; Singer, S.; Bartlett, E. K.; Crago, A. M.; Yoon, S. S.; Hwang, S.; Erinjeri, J. P.; Antonescu, C. R.; Tap, W. D.; D'Angelo, S. P. |
| Article Title: | A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma |
| Abstract: | PURPOSE: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. PATIENTS AND METHODS: This phase II study enrolled patients with advanced sarcoma into five cohorts including (i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii) leiomyosarcoma (LMS), (iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and (v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by RECIST v.1.1. RESULTS: Thirty patients were enrolled [60% male; median age 54 years (range, 24-78)]. The best ORR at 24 weeks was 3.3% [PR, n = 1 (leiomyosarcoma); two-sided 95% CI, 0.1%-17.2%]. The median PFS was 7.6 weeks (two-sided 95% CI, 6.9-26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% (n = 7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway-related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. CONCLUSIONS: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved. ©2023 American Association for Cancer Research. |
| Keywords: | adult; middle aged; genetics; clinical trial; phase 2 clinical trial; monoclonal antibody; sarcoma; leiomyosarcoma; soft tissue neoplasms; soft tissue tumor; tumor microenvironment; antibodies, monoclonal, humanized; humans; human; male; female; pembrolizumab; epacadostat |
| Journal Title: | Clinical Cancer Research |
| Volume: | 29 |
| Issue: | 11 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2023-06-01 |
| Start Page: | 2043 |
| End Page: | 2051 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-22-3911 |
| PUBMED: | 36971773 |
| PROVIDER: | scopus |
| PMCID: | PMC10752758 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in PubMed PDF -- Corresponding author is MSK author: Ciara M. Kelly -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work